Abstract
The renin-angiotensin system is primarily responsible for regulating vascular tone. Drugs that inhibit this pathway, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists, are widely used to treat hypertension and a variety of cardiomyopathies. Recent studies have shown that, in addition to reducing blood pressure, these drugs also modulate inflammation, adhesion molecule expression, and fibrosis. To assess the therapeutic potential of these inhibitory agents for the treatment of inflammatory heart disease, the drugs have been tested in experimental models of infectious and autoimmune myocarditis. This review summarizes the results of studies examining the efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists for the treatment of mouse models of virusinduced and parasite-induced myocarditis, as well as autoimmune cardiomyopathy. The collective results strongly support the use of renin-angiotensin modulation for the treatment of myocarditis. Importantly, this therapeutic approach seems to downregulate autoimmunity without causing immune suppression which may enhance the survival of the diseaseinitiating infectious agent.
Keywords: Angiotensin converting enzyme, angiotensin, renin-angiotensin system, immunity, myocarditis, autoimmunity, cardiac
Current Pharmaceutical Design
Title: Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Volume: 13 Issue: 13
Author(s): Melvin D. Daniels, Kenneth V. Hyland and David M. Engman
Affiliation:
Keywords: Angiotensin converting enzyme, angiotensin, renin-angiotensin system, immunity, myocarditis, autoimmunity, cardiac
Abstract: The renin-angiotensin system is primarily responsible for regulating vascular tone. Drugs that inhibit this pathway, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists, are widely used to treat hypertension and a variety of cardiomyopathies. Recent studies have shown that, in addition to reducing blood pressure, these drugs also modulate inflammation, adhesion molecule expression, and fibrosis. To assess the therapeutic potential of these inhibitory agents for the treatment of inflammatory heart disease, the drugs have been tested in experimental models of infectious and autoimmune myocarditis. This review summarizes the results of studies examining the efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists for the treatment of mouse models of virusinduced and parasite-induced myocarditis, as well as autoimmune cardiomyopathy. The collective results strongly support the use of renin-angiotensin modulation for the treatment of myocarditis. Importantly, this therapeutic approach seems to downregulate autoimmunity without causing immune suppression which may enhance the survival of the diseaseinitiating infectious agent.
Export Options
About this article
Cite this article as:
Daniels D. Melvin, Hyland V. Kenneth and Engman M. David, Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System, Current Pharmaceutical Design 2007; 13 (13) . https://dx.doi.org/10.2174/138161207780618812
DOI https://dx.doi.org/10.2174/138161207780618812 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skeletal Muscle Derived Stem Cells for Myocardial Repair
Recent Patents on Cardiovascular Drug Discovery Chest Pain in Children
Current Pediatric Reviews Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Bioinformatics Analysis of Functional Relations Between CNPs Regions
Current Bioinformatics The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research A Review of the Pharmacological Properties of 3,4-dihydro-2(1H)- quinolinones
Mini-Reviews in Medicinal Chemistry Drug Uptake Systems in Liver and Kidney
Current Drug Metabolism New Applications of Oleanolic Acid and its Derivatives as Cardioprotective Agents: A Review of their Therapeutic Perspectives
Current Pharmaceutical Design Mineralocorticoid Receptor Antagonism and Cardiac Remodeling in Ischemic Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Pattern of Calculated Inflammation Ratios as Prognostic Values in Patients with Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Evaluation of the Antioxidant and Antidiabetic Potential of the Poly Herbal Formulation: Identification of Bioactive Factors
Cardiovascular & Hematological Agents in Medicinal Chemistry New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Lipotoxicity Disrupts Erythrocyte Function: A Perspective
Cardiovascular & Hematological Disorders-Drug Targets PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Calcium Ions in Inherited Cardiomyopathies
Medicinal Chemistry SynB3 Conjugated QBP1 Passes Blood-Brain Barrier Models and Inhibits PolyQ Protein Aggregation
Protein & Peptide Letters Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design